|
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors. |
|
|
Research Funding - Basilea (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Roche (Inst); Sanofi (Inst) |
Research Funding - Janssen (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Basilea |
|
|
|
Stock and Other Ownership Interests - Basilea |
Research Funding - Basilea |
Patents, Royalties, Other Intellectual Property - Basilea (Inst) |
|
|
|
|
|
No Relationships to Disclose |
|
Marc Frederick Engelhardt |
|
Stock and Other Ownership Interests - Basilea |
|
|
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); BMS Brazil (Inst); MJP (Inst); Novartis (Inst); Roche (Inst) |
Research Funding - Bayer (Inst); Merck Serono (Inst) |
|
|
Research Funding - Basilea (Inst) |